JHU395 is a novel orally bioavailable prodrug of a glutamine antagonist (GA) that remains inert in plasma circulation but penetrates target tissues and releases active GA. It delivers the active glutamine antagonist to malignant peripheral nerve sheath tumors (MPNSTs) and significantly inhibits tumor growth without observable toxicity.